Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers

Status Completed

Clinical Trial Summary

This study evaluated the change in nasopharyngeal carriage (NPC) of Streptococcus pneumoniae (SPn), hypothesizing that it would be reduced post-vaccination with Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide adjuvant (PATH-wSP) and that PATH-wSP would remain safe and well-tolerated over the course of the study.

Clinical Trial Description

This study enrolled healthy Kenyan toddlers (12-15 months of age) who participated in the randomized control trial of VAC-010 (NCT02097472), as well as healthy toddlers aged 12 to 15 months who had not participated in the VAC-010 Study. All participants must have received a primary dose of pneumococcal conjugate vaccine (PCV) per local practice prior to enrollment in either VAC-010 or VAC-011. No treatments were administered during this study.

The study consisted of the following four groups:

Participants who were randomized in study VAC-010 (2:2:1 ratio), defined according to the treatment received in VAC-010:

- 1. PATH-wSP + Booster

- 2. PATH-wSP Only

- 3. Booster Only

Participants who did not participate in VAC-010:

- 4. No Intervention

Each group consisted of 2 cohorts of participants, Cohort 1 (300 µg PATH-wSP) and Cohort 2 (600 µg PATH-wSP). Enrollment into Cohorts 1 and 2 occurred sequentially; participants in groups 3 and 4 who did not receive PATH-wSP were also enrolled over time and allocated into one of the two cohorts (300 and 600 µg) in order to control for potential seasonal variation in the NPC of S. pneumoniae.

Each participant completed a total of 5 scheduled visits. For toddlers enrolled simultaneously in VAC-010, visits corresponded to enrollment (Baseline) and 4, 8, 12, and 24 weeks post final vaccination in VAC-010. For toddlers in the No Intervention group, the first visit corresponded to Baseline and the second to fifth visits corresponded to 12, 16, 20, and 32 weeks later. Nasopharyngeal swabs were taken at each visit following World Health Organization (WHO) guidelines for analysis of nasopharyngeal burden.

Treatments received during VAC-010 included:

- PATH-wSP: Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide adjuvant

- Synflorix™ booster vaccine: pneumococcal polysaccharide conjugate vaccine (adsorbed)

- Pentavac booster vaccine: diphtheria, tetanus, pertussis (Whole Cell), hepatitis B (recombinant deoxyribonucleic acid [rDNA]) and Haemophilus influenzae type b conjugate vaccine (adsorbed).

- Saline control ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02146365
Study type	Observational
Source	PATH
Contact
Status	Completed
Phase
Start date	September 25, 2014
Completion date	February 18, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04546425` - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants	Phase 3
Recruiting	`NCT06044077` - A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People	Phase 3
Completed	`NCT04525599` - A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator	Phase 1
Active, not recruiting	`NCT05512819` - A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan	Phase 3
Completed	`NCT04530838` - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants	Phase 3
Active, not recruiting	`NCT06026748` - A Phase I Study of XJ103 in Chinese Healthy Subjects	Phase 1
Completed	`NCT04526574` - Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age	Phase 3
Completed	`NCT05329259` - A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India	Phase 4
Completed	`NCT00234338` - Study Evaluating Prevenar in High-Risk Children	N/A
Completed	`NCT01767402` - Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults	Phase 1
Active, not recruiting	`NCT05569954` - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)	Phase 3
Completed	`NCT01111214` - Child Pneumococcal Serotype Epidemiology In Greece	N/A
Completed	`NCT01298544` - A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers	Phase 4
Completed	`NCT04830358` - Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults	Phase 1
Completed	`NCT04379713` - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants	Phase 3
Completed	`NCT04887948` - Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2	Phase 3
Completed	`NCT04382326` - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants	Phase 3
Not yet recruiting	`NCT00843895` - Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years	N/A
Completed	`NCT01734239` - A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)	Phase 3
Completed	`NCT05408429` - Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13	Phase 3